Table 1.
SBRT Thoracic Re-irradiation Studies
| Study | Coon et al [24] | Kelly et al [21] | Trakul et al [22] | Reyngold et al [23] | Ester et al [25] | Trovo et al [27] | Seung et al [26] |
|---|---|---|---|---|---|---|---|
| Number of Patients | 12 | 36 | 15 | 39 | 13 | 17 | 8 |
| First Radiation Dose | n/a | 61.5 Gy (range 30-79.2) | Median BED 87.5 Gy (range 60-112.5) | 61.0 Gy (30-80) | 61.2 Gy (median) | 50-60 Gy | 50-68 Gy |
| Time Between Treatments (median) | n/a | 22.0 mo (range 0-92) | 16 mo (range 5-80) | 37.0 mo (range 1-180) | 19.7 mo (range 4.7-84.7) | 18 mo (range 1-60) | 367.0 mo (range 8-57) |
| Re-irradiation Dose | 60 Gy | 50 Gy (72%), 40 Gy (17%), Other (11%) | median BED 80 Gy (60-112.5) | median BED 70.4 Gy (range 42.6-180) | 9-10 Gy x5 | 30 Gy (5-6 fx) | 12 Gy x4, 10 Gy x5, 8 Gy x5, 20 Gy x3 |
| Target Size (range) | median GTV 14.3 cc | tumor (median) 1.7 cm (range 0.6-3.8) | 14.2 ml (range 2-57.7) | median GTV 19.0 cc (0.7-227) | n/a | n/a | n/a |
| Follow up (median) | 12 mo | 15 mo (range 4-45) | 15 mo (range 4-65) | 12.6 mo (range 1.3-47.5) | 11.4 mo (0.9-38.3) | 18 mo (range 4-57) | 18 mo (range 11-20) |
| Local Control | 92% | 92% | 65.5% | 77% (1-year LPFS) | 92% | 86% | 86% |
| Overall Survival | 67% (1-year) | 59% (2-years) | 80% (1-year) | 22.0 months (MS) | n/a | 59% (1-year) | n/a |
| Toxicity | no G3 | G3 pneumonitis (28%), G3 esophagitis (8%), G3 skin (6%), G3 cough (3%), No G4/5 toxicities | chest wall pain (6.7%), esophagitis (0.9%), no G2 or higher pneumonitis, no G4 or higher toxicities | G2 pulmonary (18%), G3 pulmonary (5%), G2/3 chest wall pain (18%), G2/3 fatigue (15%), G2-4 skin toxicity (5%), no G5 toxicities | G2 pulmonary (7.7%), G3 pulmonary (7.7%), no G4 or G5 | G3 pneumonitis (23%), G5 pneumonitis (6%), G5 hemoptysis (6%) | G1 cough (13%), G1 pain (13%), G2 dyspnea (100%) |
n/a: not available; mo: months; G: grade.